The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%.
 
Elizabeth Jimenez Aguilar
No Relationships to Disclose
 
Biagio Ricciuti
No Relationships to Disclose
 
Justin F. Gainor
Honoraria - ARIAD; Incyte; Merck; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Agios; Amgen; Array BioPharma; Bristol-Myers Squibb; Genentech; Jounce Therapeutics; Loxo; Merck; Oncorus; Regeneron; Takeda; Theravance
Research Funding - Adaptimmune (Inst); Alexo Therapeutics (Inst); ARIAD; Array BioPharma (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Genentech; Jounce Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); Tesaro (Inst)
 
Mizuki Nishino
Honoraria - Bayer Yakuhin; Roche Pharma AG
Consulting or Advisory Role - Daiichi Sankyo; Toshiba; WorldCare Clinical, LLC
Research Funding - AstraZeneca (Inst); Merck (Inst); Toshiba (Inst)
 
Anika E. Adeni
No Relationships to Disclose
 
Safiya Subegdjo
No Relationships to Disclose
 
Sara Khosrowjerdi
No Relationships to Disclose
 
Rachel Peterson
No Relationships to Disclose
 
Subba Digumarthy
No Relationships to Disclose
 
Corinne Liu
No Relationships to Disclose
 
Jennifer L. Sauter
Stock and Other Ownership Interests - Merck; Thermo Fisher Scientific
 
Hira Rizvi
No Relationships to Disclose
 
Kathryn Cecilia Arbour
Consulting or Advisory Role - AstraZeneca
 
Brett W. Carter
No Relationships to Disclose
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Merck; Novartis; Spectrum Pharmaceuticals
Research Funding - AstraZeneca (Inst); Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations
 
Mehmet Altan
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst)
 
Matthew David Hellmann
Stock and Other Ownership Interests - Shattuck Labs
Honoraria - AstraZeneca; Bristol-Myers Squibb
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Janssen; Merck; Mirati Therapeutics; Nektar; Novartis; Shattuck Labs; Syndax
Research Funding - Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - A patent has been filed by Memorial Sloan Kettering (PCT/US2015/062208) for the use of tumor mutation burden for prediction of immunotherapy efficacy, and which is licensed to Personal Genome Diagnostics. (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb
 
Mark M. Awad
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Foundation Medicine; Genentech; Merck; Nektar; Novartis; Pfizer; Syndax
Research Funding - Bristol-Myers Squibb